Valeant Pharmaceuticals International Inc. hasn’t given individuals Congress all the documents they’ve sought part of a probe in to the company’s drug pricing practices, and lawmakers need to know why.
Leaders of the house Committee on Oversight and Government Reform wrote to Valeant Ceo Michael Pearson on Thursday, asking him to explain why the drugmaker hasn’t surrended the data originally requested in August, with different statement from Committee Chairman Jason Chaffetz, a Republican from Utah, as well as the ranking Democrat across the committee, Representative Elijah Cummings of Maryland.
Valeant didn’t immediately respond to requests for comment.
The committee held a hearing recently in price increases with the pharmaceutical industry, and grilled Valeant together with controversial former drug executive Martin Shkreli.
Related
- Martin Shkreli invokes Fifth Amendment as Valeant, Turing take part in fire at congressional hearingFew positives seen for Valeant Pharmaceuticals International Inc before March 15 conference call
-
-
-
Valeant provides documents it considers “nonprivileged,” in line with the statement. Chaffetz and Cummings asked Pearson to supply a listing describing each document the organization has withheld and also the cause of not turning it towards the committee.
“Using the information you provide responding with this request, the committee can assess the reason for your decision to withhold these documents and discover whether, and to what extent, such documents needs to be provided,” the lawmakers wrote.
Valeant has additionally didn’t provide transcribed interviews with executives and documents related to its now-severed relationship with a mail-order pharmacy, according to Chaffetz and Cummings.
— Using Cynthia Koons.
Bloomberg News
